From the April 2021 issue of HealthCare Business News magazine
In addition to reducing radiation exposure, the positioning of CorPath GRX provides the operating physician with greater visualization of the case than they would have if using manual PCI, due to closer proximity to the angiographic images.
AI software for cardiac echo could help in COVID-19 fight
A U.K. company with software that uses AI to predict the likelihood of a patient developing coronary artery disease entered into a clinical research agreement with Mayo Clinic in late May to further develop the product.
The partnership will also explore using AI analysis of echocardiograms to potentially help triage COVID-19 patients, as heart disease is associated with worse outcomes.
Ultromics, which spun out of research at Oxford University, markets the EchoGo Core and EchoGo Pro, which applies AI to echocardiograms to better diagnose heart disease.
The EchoGo Core product, which is FDA cleared, provides automated scores for ejection fraction and Global Longitudinal Strain. Without the device, the scores are only 76% accurate and highly variable based on which clinician performs the calculations, said Ross Upton, Ultromics’ chief executive officer.
The company’s EchoGo Pro product, which is CE marked but has not yet been submitted for FDA clearance, predicts whether a patient is at risk of a heart attack and requires intervention.
The partnership will allow Ultromics to use Mayo Clinic’s extensive cardiac data sets to help develop the company’s image analysis product suite. Mayo Clinic will use EchoGo Core to analyze echocardiograms of COVID-19 patients, to better understand how the virus affects the cardiovascular system.
Ziehm Imaging acquires French-based imaging software developer Therenva
With the acquisition of Therenva in late July, Ziehm Imaging is aiming to leverage its distribution network of mobile C-arms to market the French-based software developer's imaging software portfolio globally.
Building on a two-year market cooperation in Europe, the combined companies will focus on the cardiovascular image fusion and 3D navigation solutions. Further down the line, the combined companies are poised to develop new solutions for pre- and intraoperative image-based decision support in cardiovascular, and potentially other clinical areas.
“We are really excited to extend our partnership and work even closer together with the committed team at Therenva,” Klaus Hörndler, CEO at Ziehm Imaging, said in a statement. “The Therenva portfolio is the perfect addition to our leading C-arm portfolio, and we look very much forward to further driving the OR integration in the future together.”
